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Abstract
Background: The use of impedance cardiography (ICG) revealed to provide beneficial blood 
pressure (BP) lowering effect. However, the follow-up in previous trials was short and brachial 
BP was the only evaluated hemodynamic variable. Thus, we aimed to estimate the influence of 
ICG-guided therapy on brachial and central BP, impedance-derived hemodynamic profile and 
echocardiographic features after 12 months in a randomized, prospective and controlled trial 
(NCT01996085).
Methods: One hundred and forty-four hypertensives were randomly assigned to groups of 
empiric (GE) and ICG-guided therapy (HD). Office BP, ambulatory BP monitoring, central 
BP and echocardiography (left ventricular hypertrophy and diastolic function assessment) were 
performed before and after 12 months of treatment.
Results: Blood pressure reduction was higher in HD (office BP: 21.8/14.1 vs. 19.9/11.8 mm Hg;  
mean 24-h BP: 19.0/10.9 vs. 14.4/9.2 mm Hg). However, the only statistically significant  
differences were: percentage of patients achieving BP reduction of minimum 20 mm Hg for of-
fice diastolic BP (27.3% vs. 12.1%; p = 0.034) and mean 24-h systolic BP (49.1% vs. 27.3%; 
p = 0.013). More pronounced improvement in the left ventricular diastolic dysfunction (delta 
E/A 0.34 vs. 0.12, p = 0.017) was the only other beneficial hemodynamic effect.
Conclusions: Beneficial BP lowering effect of hemodynamically-guided pharmacotherapy, 
observed previously in short-term observation, persists over time. Hemodynamic effects of such 
a treatment approach, especially those of prognostic value (central BP, myocardial hypertrophy), 
should be evaluated in further studies including patients with resistant hypertension, heart 
failure, diabetes mellitus and chronic kidney disease. (Cardiol J 2016; 23, 2: 132–140)
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Introduction
Arterial hypertension (AH) is the main wide-
spread cardiovascular risk factor in the world’s 
population. Unfortunately, the majority of hyper-
tensives still do not achieve satisfactory blood 
pressure (BP) control [1, 2]. Current guidelines 
[2, 3] emphasize a need for personalized hypotensive 
therapy. It may be supported by individualized as-
sessment of hemodynamic alterations associated 
with increased BP. One of the promising diagnos-
tic techniques is impedance cardiography (ICG), 
useful in the identification of hyperdynamic heart 
function, fluid retention, and increased vascular 
resistance. Hemodynamically-guided pharmaco-
therapy based on impedance variables, such as 
cardiac index (CI), thoracic fluid content (TFC) and 
systemic vascular resistance index (SVRI), was 
previously evaluated in randomized, prospective 
and controlled trials and revealed to be more ben-
eficial than the empiric treatment [4–8]. However, 
the period of observation in those trials was short 
(3 months) and BP reduction was the only evalu-
ated hemodynamic effect.
Thus, there is no evidence (1) if this effect per-
sists in longer observation period and (2) whether 
this therapeutic approach has influence on other 
features related to cardiovascular hemodynamics, 
especially these of prognostic value (central BP, 
myocardial hypertrophy) [2, 9].
Therefore, the aim of this study was to esti-
mate the influence of ICG-guided antihyperten-
sive therapy on: (1) brachial and (2) central BP, 
(3) impedance-derived hemodynamic profile and 
(4) echocardiographic indices of left chambers’ 
morphology and function evaluated after 12 months 
in a randomized, prospective and controlled trial.
Methods
Study population
The study group consisted of patients with at 
least 3-month history of AH defined according to 
the European Society of Cardiology (ESC) guide-
lines [2]. Exclusion criteria were: (1) confirmed 
secondary AH, (2) AH treated with three or more 
medicines before recruitment, (3) significant heart 
failure (left ventricular ejection fraction < 45%), 
(4) cardiomyopathy (i.e. hypertrophic cardio-
myopathy), (5) significant heart rhythm disorders, 
(6) significant valvular disease, (7) kidney failure 
(estimated glomerular filtration rate < 60 mL/ 
/min/1.73 m2), (8) chronic obstructive pulmonary 
disease, (9) diabetes, (10) polyneuropathy, (11) 
peripheral vascular disease, (12) age < 18 years.
Study group comprised of patients recruited 
for prospective, randomized and controlled study, 
performed in the Department of Cardiology and 
Internal Diseases of Military Institute of Medicine 
(ClinicalTrials.gov NCT01996085) and conducted 
according to the Good Clinical Practice guidelines 
and the Declaration of Helsinki, with the approv-
als of the local ethics committee. Each patient 
provided written informed consent to participate 
in the study.
Study design
The study was randomized (1:1), prospective 
and simultaneously controlled by conventional 
treatment. Initial clinical evaluation was performed 
via face to face or telephone conversations. Patients 
who had taken medicines before the study were 
advised to discontinue using them (minimum 7 days 
of pharmacological “wash-out”). Next, all patients 
underwent complete clinical examination including: 
interview and physical examination, office blood 
pressure measurement (OBPM), ambulatory blood 
pressure monitoring (ABPM), impedance cardiogra-
phy, applanation tonometry, and echocardiography.
The subjects were allocated to two groups ac-
cording to the pre-established random order (by us-
ing the method of randomly permuted blocks avail-
able at www.randomization.com): (1) empiric (GE) 
and (2) hemodynamic (HD). Treatment choice in 
both groups was made by independent researchers.
The evaluation of treatment effects was per-
formed after 12 months and blinded to the group 
allocation. Differences between groups in BP re-
duction and obtained BP control were considered 
main final points (per protocol analysis). Figure 1 
shows the protocol flowchart for observation 
time of mean 376 ± 25 days. The subjects were 
evaluated 3 times (no additional interim visits were 
performed). Twenty-three patients were excluded 
from the final analysis (GE: 7 subjects; HD: 16 sub-
jects). Twenty-two of them resigned from control 
visit and 1 woman stopped the pharmacotherapy 
due to pregnancy. The final analysis comprised of 
121 subjects (Fig. 1).
Office blood pressure measurement
Office systolic and diastolic blood pressure 
measurement was performed during morning 
hours (7.30 a.m.–8.30 a.m.) automatically (Omron 
M4 Plus, Japan) by a technique compliant with the 
ESC guidelines [2].
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Ambulatory blood pressure monitoring
Ambulatory blood pressure monitoring started 
in the morning hours (Spacelabs 90207, Spacelabs, 
Medical Inc., Redmond, USA). Time from 6 a.m. to 
10 p.m. was considered daily activity period (day-
time) with automatic BP measurements in 10-min 
intervals. During night rest (10 p.m.–6 a.m.) the 
measurements were performed every 30 min. Pa-
tients were recommended to adjust their circadian 
activity to those periods of time. BP thresholds 
used to define AH were set according to the ESC 
guidelines [2].
Applanation tonometry
The assessment of central BP and augmen-
tation index (AI) was performed noninvasively 
using the SphygmoCor® system (AtCor Medical 
Inc Pty Ltd, Sydney, Australia). Radial artery pres-
sure waveforms were recorded at left wrist using 
applanation tonometry with a high-fidelity micro-
manometer (Millar Instruments, Houston, Texas) 
and processed by SphygmoCor® software (version 
9.0; AtCor Medical Inc Pty Ltd., Sydney, Australia). 
Corresponding aortic pressure waveform was 
generated using a validated transfer function [10]. 
As a result, central systolic blood pressure (CSBP 
[mm Hg]), central diastolic blood pressure (CDBP 
[mm Hg]) and central pulse pressure (CPP [mm Hg]) 
were derived. Augmentation pressure (AP [mm 
Hg]) was calculated as the maximum systolic pres-
sure minus pressure at the inflection point and AI 
([%]) as AP × 100/CPP.
Echocardiography
Two-dimensional echocardiography was per-
formed using standard parasternal, apical, and 
subcostal views (2.5 MHz transducer; VIVID S6 
GE Medical System, Wauwatosa, WI, USA). The 
dimensions of left atrium (LA), left ventricular end 
diastolic diameter (LVEDD) and interventricular 
septum diameter were measured in the parasternal 
long-axis view in the late diastole of the LA and 
left ventricle (LV), respectively. Left ventricular 
ejection fraction was calculated according to the 
Simpson’s formula. The left ventricular hypertro-
phy (LVH) was diagnosed according to the formula 
recommended by the American Society of Echo-
cardiography for estimation of the left ventricular 
Figure 1. The flowchart of patients (numbers of discontinued interventions after 12 months are cumulative); 
ABPM — ambulatory blood pressure monitoring; AT — applanation tonometry; ICG — impedance cardiography; 
OBPM — office blood pressure measurement.
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mass index (LVMI), indexed to body surface area 
(cutoff values for men LVMI >115 g/m2, for women 
> 95 g/m2).
Mitral valve inflow was recorded in the apical 
4-chamber view with pulsed wave Doppler gate 
positioned in LV at the level of mitral valve edges. 
The following parameters were measured: mitral 
inflow early (E) and late (A) phase ratio (E/A) and 
phase E deceleration time. Tissue Doppler imag-
ing was performed in the apical views to acquire 
mitral annular velocity, mitral septal annulus early 
diastolic velocity (e’) was measured and based on 
this the E/e’ ratio was calculated. Diagnosis of the 
LV diastolic dysfunction was based on the current 
guidelines [11]. The study group comprised only 
of patients with normal and mildly impaired LV 
diastolic function (impaired relaxation diastolic 
filling pattern).
Impedance cardiography
All ICG measurements were performed using 
the Niccomo™ device (Medis, Ilmenau, Germany) 
after 10 min of rest in a supine position. Blood pres-
sure measurement was performed automatically 
every 2 min with an arm cuff. Other hemodynamic 
parameters were measured with a beat-to-beat 
method. The TFC, CI, SVRI, heart rate (HR) values 
measured in the 5th min of the examination were 
taken into account in the treatment algorithm. 
The cutoff values for TFC, SVRI, CI and HR (from 
the 5th min of ICG examination) defined hemody-
namic profile: (1) hyperconstrictive: in case of SVRI 
> 2500 dyn/s/m2/cm5, (2) hyperdynamic: CI > 4.2 
l/min/m2 and/or HR > 80/min, (3) hypervolemic 
profile: TFC > 34 1/kOhm for men and > 24 
1/kOhm for women, (4) balanced profile — hemo-
dynamic parameters below established threshold 
values. The subjects requiring combined therapy 
with regard to significantly increased BP (average 
office BP > 160/100 mm Hg and/or average 24-h 
BP > 140/90 mm Hg) were also distinguished.
Treatment
Non-pharmacological treatment was adminis-
tered according to the current ESC guidelines [2]. 
Pharmacotherapy included: lisinopril (angiotensin 
converting enzyme inhibitor [ACEI]), telmisartan 
(angiotensin receptor blocker [ARB]), hydro-
chlorothiazide/indapamide (diuretic), metoprolol/ 
/nebivolol (beta-blocker [BB]), amlodipine (calcium 
blocker [CB]).
The arbitrarily predetermined treatment al-
gorithm in HD group was based on our own data 
collected in the cohort of hypertensive patients 
and the analysis of the previous reports [5, 6, 12– 
–15]. Cutoffs for CI and SVRI were adopted from 
the previous studies of Taler et al. [5] and Smith 
et al. [6]. Increased rest HR (> 80/min) was consid-
ered an indication for BB use due to the fact that it 
had been reported to be unfavorable for prognosis 
[15]. The different cut-off values for TFC for men 
and women were defined based on sex-dependant 
computational calculation used in Niccomo device.
The first step of drug choice was based on the 
hemodynamic profile (hyperdynamic profile — BB, 
hypervolemic — diuretic, hyperconstrictive — 
vasodilator/s). Combined therapy was applied in 
cases of complex hemodynamic disturbances and 
to patients demanding combined polytherapy (BP 
criteria mentioned above). This algorithm was 
described in detail in our previous study [7]. Pa-
tients in the GE group were treated according to 
the current ESC guidelines [2]. With most patients 
the first drug choice was ACEI and CB, the most 
preferred combinations were: ACEI with diuretic 
and ACEI with CB.
Statistical analysis
On the basis of the results of the previous 
studies [5–7], the sample size for minimum change 
in BP reduction of 6 mm Hg after 12 months of 
follow-up was calculated as 45 patients per treat-
ment group (a-error 5%, statistical power 80%). 
The statistical analysis was performed using 
Statistica 7.0 (StatSoft, Inc., Tulsa, USA). The dis-
tribution and normality of the data were assessed 
by visual inspection and the Kolmogorov-Smirnov 
test. Continuous variables were presented as 
means ± standard deviation. Treatment effects 
were compared with the use of ANOVA/Mann-
-Whitney U-test for continuous variables (change 
in BP) and c2 test/Fisher’s exact test for categori-
cal variables (percentage of achieved reduction 
in BP of minimum 10 mm Hg/20 mm Hg). The 
change of chosen variables was calculated as 
[delta] = [absolute value after 12 months] – [base-
line absolute value]. P < 0.05 was considered 
statistically significant.
Results
Baseline clinical data
The final analysis involved 121 patients (83 
men) of average age 46.4 ± 10.1 years (spread 
from 20 to 68 years). Most of them (81.0%) were 
mildly hypertensive (grade 1) and only 19.0% of 
them presented AH grade 2 or 3. 20.7% of them 
were previously treated with hypotensive drugs. 
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Table 1. Basic characteristics; data presented as mean ± standard deviation and numbers (percent-
ages); no statistically significant differences between empiric (GE) group and hemodynamic group (HD) 
were noted.
Variable Whole group (n = 121)
GE (n = 66) HD (n = 55)
Men 47 (71.2%) 36 (65.5%)
Age [years] 46.1 ± 9.8 46.7 ± 10.5
Body mass index [kg/m2] 28.7 ± 4.1 29.2 ± 4.0
Office SBP [mm Hg] 140.9 ± 12.9 142.0 ± 14.3
Office DBP [mm Hg] 90.0 ± 9.5 90.8 ± 9.6
Mean 24-h SBP [mm Hg] 139.5 ± 12.0 142.1 ± 11.9
Mean 24-h DBP [mm Hg] 88.2 ± 7.8 88.3 ± 11.9
Left ventricular hypertrophy 9 (13.6%) 4 (7.3%)
Left ventricular diastolic dysfunction 20 (30.3%) 12 (21.8%)
DBP — diastolic blood pressure; SBP — systolic blood pressure
No significant differences in basic clinical char-
acteristics between GE and HD subjects were 
observed (Table 1).
Treatment effects — brachial blood pressure
Reduction of BP absolute values due to treat-
ment was observed in both groups. However, no 
statistically significant difference between GE 
and HD was noted (Table 2). The benefit from the 
hemodynamically-guided therapy revealed to be 
more evident when comparing delta systolic BP 
(Fig. 2) but the differences still did not reach sta-
tistical significance. The only statistically signifi-
cant differences were obtained for the percentage 
of patients achieving BP reduction of minimum 
20 mm Hg for office diastolic BP and mean 24-h 
systolic BP (Fig. 3).
Treatment effects — impedance  
cardiography, applanation tonometry  
and echocardiography
The use of ICG did not significantly influence 
the effects of 12-month therapy on other analyzed 
hemodynamic and echocardiographic characteristics. 
There were no significant differences between GE 
and HD in central BP, basic impedance indices (HR, 
CI, TFC, SVRI), left chamber dimensions (LVEDD, 
LA), cardiac muscle mass (LVMI) and echocardio-
graphic indices of LV diastolic function (Table 3). 
However, the analysis in a subgroup of patients with 
LV diastolic dysfunction revealed slightly a better 
effect of hemodynamically-guided intervention 
— better improvement (change) in E/A (GE vs. 
HD: 0.12 vs. 0.34, p = 0.017), e’ (2.67 vs. 2.13 cm/s, 
p = 0.699) and E/e’ (–0.77 vs. –0.82, p = 0.839). 
Table 2. Blood pressure values within subsequent visits; data presented as mean ± standard deviation, 
no statistically significant differences between empiric (GE) group and hemodynamic group (HD)  
for respective variables.
Variable GE (n = 66) HD (n = 55)
1st visit 2nd visit 3rd visit P 1st visit 2nd visit 3rd visit P
Office SBP 
[mm Hg]
140.9 ± 12.9 124.1 ± 11.8 120.9 ± 10.8 < 0.00001 142.0 ± 14.3 123.5 ± 9.9 120.2 ± 8.1 < 0.00001
Office DBP 
[mm Hg]
90.0 ± 9.5 81.0 ± 10.0 78.2 ± 6.4 < 0.00001 90.8 ± 9.6 79.4 ± 6.7 76.7 ± 6.4 < 0.00001
Mean 24-h 
SBP [mm Hg]
139.5 ± 12.0 126.1 ± 11.5 125.0 ± 9.9 < 0.00001 142.1 ± 11.9 124.9 ± 11.5 123.1 ± 8.9 < 0.00001
Mean 24-h 
DBP [mm Hg]
88.2 ± 7.8 78.9 ± 8.3 78.9 ± 7.4 < 0.00001 88.3 ± 11.9 78.2 ± 7.8 77.4 ± 6.7 < 0.00001
DBP — diastolic blood pressure; SBP — systolic blood pressure
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Figure 2. The comparison of the effect between empiric (GE) and hemodynamically guided treatment (HD) within 
BP change (p value presented on the bars); DBP — diastolic blood pressure; SBP — systolic blood pressure.
Figure 3. The comparison of the effect between empiric 
(GE) and hemodynamically guided treatment (HD) with-
in achieved reduction in blood pressure of minimum 
10 mm Hg (A) and of minimum 20 mm Hg (B); DBP — 
diastolic blood pressure; SBP — systolic blood pressure.
Such an analysis was not performed in the subgroup 
of patients with LVH because of low sample size 
(n = 13).
Pharmacotherapy
The most commonly administered drugs in 
both groups were renin–angiotensin–aldosterone 
system’s blockers (ACEI/ARB) and diuretics 
(Table 4). The GE patients were more frequently 
treated with ACEI and CB, whereas the HD 
patients with diuretics and BB. However, no 
statistically significant difference was noted. 
Likewise, the percentage of patients demanding 
intensification of pharmacotherapy during sec-
ond visit was comparable (GE vs. HD: 19.7% vs. 
18.2%, p = 0.832).
Discussion
Blood pressure control still remains a chal-
lenge in AH. Thus, the search for noninvasive 
tools useful in individualized hemodynamic 
assessment of hypertensives seems to be justi-
fied. We present the results of FINEPATH study 
which aimed at evaluating whether the benefi-
cial effect of hemodynamically-guided therapy, 
previously reported in short-term observations, 
persisted over 1 year and whether it was visible 
in other clinically relevant characteristics. Our 
results encourage the use of ICG while choos-
ing the antihypertensive pharmacotherapy. We 
observed clinically relevant better BP lowering 
effect and slightly more pronounced improve-
ment of the LV diastolic function in subjects 
treated according to ICG-based algorithm. No 
significant differences were observed in left 
chambers morphology, LV systolic function and 
central BP.
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Table 3. Treatment effects assessed by impedance cardiography, applanation tonometry and echo-
cardiography; data presented as mean ± standard deviation and numbers (percentages).
Variable Empiric group  
(n = 66)
Hemodynamic group  
(n = 55)
P
Impedance cardiography
Delta HR [bpm] –2.4 ± 9.6 –5.5 ± 10.6 0.092
Delta CI [l/min/m2] –0.06 ± 0.59 –0.11 ± 0.70 0.831
Delta TFC [1/kohm] –0.43 ± 4.6 0.79 ± 3.57 0.164
Delta SVRI [dyn*s*m2/cm5] –280.6 ± 433.8 –251.7 ± 426.1 0.873
Applanation tonometry
Delta CSBP [mm Hg] 16.7 ± 14.6 14.2 ± 14.0 0.345
Delta CDBP [mm Hg] 11.6 ± 10.0 11.2 ± 9.0 0.942
Delta CPP [mm Hg] 5.1 ± 8.4 3.2 ± 9.2 0.243
Delta AI [%] 0.74 ± 11.1 0.04 ± 10.1 0.595
Echocardiography
Delta LVEDD [mm] 0.10 ± 1.69 –0.28 ± 3.50 0.312
Delta LA [mm] 0.50 ± 2.51 0.74 ± 2.27 0.592
Delta LVMI [g/m2] –0.53 ± 15.0 2.33 ± 14.0 0.579
Delta e’ [cm/s] 0.80 ± 2.67 0.90 ± 2.39 0.830
Delta E/e’ [–] –0.22 ± 1.93 –0.26 ± 1.97 0.682
Delta E/A [–] 0.06 ± 0.32 0.12 ± 0.33 0.229
Delta LVEF [%] 1.26 ± 4.17 1.58 ± 4.24 0.656
AI — augmentation index; CI — cardiac index; CDBP — central diastolic blood pressure; CSBP — central systolic blood pressure; CPP — cen-
tral pulse pressure; e’ — mitral septal annulus early diastolic velocity; E/A — mitral flow early (E) and late (A) phase ratio; E/e’ — mitral flow 
early (E) phase and mitral septal annulus early diastolic velocity (e’) ratio; HR — heart rate; LA — left atrium diameter; LVEDD — left ventricu-
lar end diastolic diameter; LVEF — left ventricular ejection fraction; SVRI — systemic vascular resistance index; TFC — thoracic fluid content
Table 4. Pharmacotherapy (data presented as numbers (percentages).
Empiric group (n = 66) Hemodynamic group (n = 55) P
ACE inhibitor 52 (78.8) 38 (69.1) 0.224
ARB 8 (12.1) 8 (14.6) 0.695
Diuretics 17 (25.8) 23 (41.8) 0.062
Beta-blocker 11 (16.7) 16 (29.1) 0.102
Calcium blocker 12 (18.8) 7 (12.7) 0.412
ACE — angiotensin converting enzyme; ARB — angiotensin receptor blocker
Blood pressure (brachial) lowering effects
Our results suggest persistent benefit from the 
hemodynamically-guided antihypertensive therapy. 
Patients treated according to ICG achieved slightly 
greater BP reduction in both OBPM and ABPM. 
That effect was more pronounced among those 
with higher BP reduction (Fig. 3B). However, 
the statistical significance was achieved only for 
percentage of patients achieving BP reduction of 
minimum 20 mm Hg for office diastolic BP and 
mean 24-h systolic BP. The uncertainty of other 
results seems unlikely because better BP reduc-
tion was observed independently in OBPM and 
ABPM. Even those statistically non-significant 
differences we interpret as clinically important 
because a slight decrease in BP revealed to be 
related to lower risk of overall mortality, coronary 
disease and stroke [16]. We suppose that the ex-
pected benefit from the ICG-guided therapy was 
limited by sample size and the early stage of AH 
(see more in ‘Limitations of the study’ section). 
We would also like to emphasize that subjects in 
GE were treated by experienced cardiologists, of 
higher expertise than general practitioners, which 
carry the main weight of medical care over young 
hypertensives. It could cause underestimation of 
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the expected advantage of ICG in the real world 
of ambulatory care.
Our results are in line with previous studies 
in this area evaluating the effect of ICG-guided 
therapy in short-term observation [5–7, 17]. Smith 
et al. [6] evaluated 164 patients with essential AH 
and obtained better office BP control in HD group 
(77% vs. 57%, p < 0.001). In another prospective, 
randomized and controlled trial Taler et al. [5] used 
ICG-based therapy in 104 resistant hypertensives 
(average BP 171/89 mm Hg) and also achieved 
higher frequency of goal office BP in HD group 
(56% vs. 33% in GE group, p < 0.05). Likewise, 
Fadl Elmula et al. [17], in a small sample of pa-
tients with resistant AH (n = 19), reported better 
BP lowering effect of pharmacotherapy adjusted 
to the individual hemodynamic profile than renal 
denervation. The effect of ICG-guided therapy in 
aforementioned study was less impressive than 
ours but the characteristics of our population were 
also different. Lower baseline BP could signifi-
cantly limit the disclosure of advantage from indi-
vidualized treatment. As revealed in our previous 
analysis the benefit from ICG-guided therapy rose 
with the complexity of AH and was observed only 
in subjects with higher baseline BP [18].
Out-of-brachial BP lowering effects
We did not observe any benefit of the interven-
tion in the analysis of change in the left chamber 
dimensions and LV muscle mass, as it was reported 
by Fagard et al. [19]. In that metaanalysis, the re-
duction of LVMI was clinically relevant (11.0% ± 
± 0.60%, p < 0.001) but almost half of the patients 
(43.6%) presented with baseline LVH. Moreover, 
the authors proved that regression of LVH was 
related to longer study duration. No influence of 
antihypertensive treatment on LVMI in our study 
cohort can be explained by early stage of cardio-
vascular dysfunction (hypertensives without any 
other serious diseases), very low prevalence of 
LVH (10.7%) and 12-month (quite short) period 
of follow-up.
The comparative analysis did not reveal any 
intergroup difference in change of impedance pa-
rameters characterizing the hemodynamic profile. 
However, those results could be influenced by 
different, even opposite, hemodynamic action of 
drugs. Relatively high standard deviations of those 
variables suggest that the individual effects were 
underestimated by the use of averaging in general 
comparison. True hemodynamic effects could be 
revealed in separate analysis of subgroups (treated 
with different classes of drugs) which was not con-
ducted because of small sample size.
The trend to greater HR reduction in HD could 
partly explain why the higher brachial BP reduction 
was not reflected in central BP change. It could be 
a result of more frequent use of BB in HD which was 
less effective in central BP lowering than vasodila-
tors (preferred in GE) [20]. The mechanism was 
explained in a simple manner by Nieminen et al. [21]. 
Beta-blocker slows down the HR, increases the 
filling time of the LV and stroke volume. As a result, 
the pulsatile LV outflow and CPP increase.
Pharmacotherapy
Although some trends in the analysis of phar-
macotherapy were observed (subjects in GE were 
more frequently treated with vasodilators and in 
HD with diuretics and BB), they did not reveal 
significant differences between GE and HD. It 
suggests that in comparison to our previous study 
[7], empiric treatment was more intensive. It 
could partly explain slightly lower advantage of 
hemodynamically-guided intervention.
Limitations of the study
We are aware that the main limitation of the 
study was the sample size, which influenced the 
statistical power of the comparison. Basing on the 
previous studies [5–7] we calculated the sample 
size (45 per group) assuming intergroup difference 
(GE vs. HD) in delta BP as 6 mm Hg. Finally, the 
highest observed difference in our analysis was 
4.6 mm Hg (delta 24-h mean systolic BP). According 
to the statistical approach (power analysis), the sam-
ple size in this case should not be less than 76 per 
group. The fact of enrollment of relatively healthy 
patient cohort also mattered. We are aware that our 
results should be extrapolated on general popula-
tion with care because we recruited hypertensives 
without other serious chronic diseases. On the other 
hand, the time of follow-up (12 months) might be 
too short to reveal some of the evaluated long-term 
effects of the intervention (i.e. heart remodeling).
Conclusions
1. Impedance cardiography offers an effective 
option of individualized drug selection in AH. 
2. Some patients can benefit from the hemody-
namically-guided pharmacotherapy in signifi-
cantly greater BP reduction.
3. The effect of hemodynamically-guided 
pharmacotherapy persists over time.
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4. Hemodynamic effects of such treatment ap-
proach, especially those of prognostic value 
(central BP, myocardial hypertrophy), should be 
evaluated in further studies including patients 
with resistant hypertension, heart failure, 
diabetes mellitus and chronic kidney disease.
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